5 January 2012 - The Muscular Dystrophy Association (MDA) said on Thursday that it granted USD1m (EUR778,000) to Tivorsan Pharmaceuticals Inc, a US-based biotechnology company developing a novel protein therapeutic to combat Duchenne Muscular Dystrophy (DMD).

The funds will be used to help ...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up